Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: Evidence and unanswered questions

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 2, 2014, Pages 118-135

  Cheng, J W ^a   Barillari, G ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

apixaban; dabigatran; rivaroxaban; thromboembolic disorders

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CANADA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CREATININE CLEARANCE; DRUG INTERACTION; DRUG MECHANISM; EMBOLISM; EUROPE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; MEDLINE; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY (TOPIC); PEER REVIEW; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE HEPATIC IMPAIRMENT;

APIXABAN; DABIGATRAN; RIVAROXABAN; THROMBOEMBOLIC DISORDERS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CARDIOVASCULAR DISEASES; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; STROKE; THIOPHENES;

EID: 84895541979     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12122     Document Type: Review

References (82)

1. Goldhaber SZ,. Pulmonary embolism thrombolysis: a clarion call for international collaboration. J Am Coll Cardiol, 1992; 19: 246-247.
2. Fuster V, Rydén LE, Cannom DS, et al,. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006; 114: e257-e354.
3. Roger VL, Go AS, Lloyd-Jones DM, et al,. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation, 2012; 125: e2-e220.
4. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012; 141: e44S-e88S.
5. You JJ, Singer DE, Howard PA, et al,. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2012; 141: e531S-e575S.
6. Boehringer Ingelheim International GmbH. Pradaxa® (dabigatran etexilate) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000829/WC500041059.pdf (accessed 5 November 2013).
7. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® (dabigatran etexilate) Prescribing Information. 2013. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/022512s017lbl.pdf (accessed 23 October 2013).
8. Boehringer Ingelheim Canada Ltd. Pradax™ (dabigatran etexilate mesilate) Product Monograph. 2013. Available at: http://www.boehringer- ingelheim.ca/content/dam/internet/opu/ca-EN/documents/humanhealth/ product-monograph/Pradax-pm.pdf (accessed 11 November 2013).
9. Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000944/WC500057108.pdf (accessed 1 November 2013).
10. Janssen Pharmaceuticals Inc. Xarelto® (rivaroxaban) Prescribing Information. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2013/022406s004lbl.pdf (accessed 23 July 2013).
11. Bayer Inc. Product Monograph (Canada). 2013. Available at: http://www.bayer.ca/files/XARELTO-PM-ENG-28AUG2013-164839.pdf?# (accessed 18 December 2013).
12. Bristol-Myers Squibb, Pfizer EEIG. Eliquis® (apixaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/002148/WC500107728.pdf (accessed 22 October 2013).
13. Bristol-Myers Squibb Company, Pfizer Inc. Eliquis® (apixaban) Prescribing Information. 2012. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/202155s000lbl.pdf (accessed 23 October 2013).
14. Bristol-Myers Squibb Canada Inc, Pfizer Canada Inc. Eliquis (apixaban) Product Monograph. 2012. Available at: http://www.bmscanada.ca/static/products/ en/pm-pdf/ELIQUIS-EN-PM.pdf (accessed 11 November 2013).
15. Medscape. EU Approves Xarelto for Secondary Prevention after an ACS. 2013. Available at: http://www.medscape.com/viewarticle/804734 (accessed 3 July 2013).
16. Eikelboom JW, Weitz JI,. New anticoagulants. Circulation, 2010; 121: 1523-1532.
17. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W,. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem, 2002; 45: 1757-1766.
18. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F,. The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat Rev Drug Discov, 2011; 10: 61-75.
19. Wong PC, Crain EJ, Xin B, et al,. Apixaban, an oral, direct and highly selective Factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost, 2008; 6: 820-829.
20. Wong PC, Pinto DJ, Zhang D,. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis, 2011; 31: 478-492.
21. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos, 2008; 36: 386-399.
22. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G,. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther, 2005; 78: 412-421.
23. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D,. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos, 2009; 37: 1056-1064.
24. Raghavan N, Frost CE, Yu Z, et al,. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos, 2009; 37: 74-81.
25. Rule AD, Bailey KR, Schwartz GL, Khosla S, Lieske JC, Melton LJ III,. For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int, 2009; 75: 1071-1078.
26. Härtter S, Yamamura N, Stangier J, Reilly PA, Clemens A,. Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate. Thromb Haemost, 2012; 107: 260-269.
27. Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K,. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol, 2008; 48: 1411-1419.
28. Stangier J, Rathgen K, Stahle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet, 2010; 49: 259-268.
29. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M,. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol, 2005; 61: 873-880.
30. Mueck W, Eriksson BI, Bauer KA, et al,. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet, 2008; 47: 203-216.
31. Kubitza D, Becka M, Roth A, Mueck W,. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin, 2008; 24: 2757-2765.
32. Kubitza D, Becka M, Roth A, Mueck W,. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor. J Clin Pharmacol, 2013; 53: 249-255.
33. Jiang J, Hu Y, Zhang J, et al,. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban-an oral, direct Factor Xa inhibitor-in elderly Chinese subjects. Thromb Haemost, 2010; 103: 234-241.
34. Kubitza D, Becka M, Zuehlsdorf M, Mueck W,. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol, 2007; 47: 218-226.
35. Kubitza D, Roth A, Becka M, et al,. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban-an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol, 2013; 76: 89-98.
36. Zhao X, Sun P, Zhou Y, et al,. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol, 2009; 68: 77-88.
37. Tanigawa T, Kaneko M, Hashizume K, et al,. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet, 2013; 28: 59-70.
38. Kubitza D, Becka M, Mueck W, et al,. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol, 2010; 70: 703-712.
39. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M,. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects. Int J Clin Pharmacol Ther, 2007; 45: 335-344.
40. Kubitza D, Becka M, Zuehlsdorf M, Mueck W,. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol, 2006; 46: 549-558.
41. Stampfuss J, Kubitza D, Becka M, Mueck W,. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther, 2013; 51: 549-561.
42. Upreti VV, Wang J, Barrett YC, et al,. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol, 2013; 76: 908-916.
43. Frost C, Wang J, Nepal S, et al,. Apixaban, an oral, direct Factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol, 2013; 75: 476-487.
44. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol, 2007; 64: 292-303.
45. Stangier J, Stähle H, Rathgen K, Fuhr R,. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet, 2008; 47: 47-59.
46. Stangier J, Feuring M,. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis, 2012; 23: 138-143.
47. Samama MM, Martinoli JL, Le Flem L, et al,. Assessment of laboratory assays to measure rivaroxaban-an oral, direct Factor Xa inhibitor. Thromb Haemost, 2010; 103: 815-825.
48. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE,. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit, 2010; 32: 673-679.
49. Mani H, Rohde G, Stratmann G, et al,. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost, 2012; 108: 191-198.
50. Samama MM, Contant G, Spiro TE, et al,. Evaluation of the anti-Factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost, 2012; 107: 379-387.
51. Hartter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J,. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol, 2013; 69: 327-339.
52. Hartter S, Sennewald R, Nehmiz G, Reilly P,. Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol, 2013; 75: 1053-1062.
53. Härtter S, Koenen-Bergmann M, Sharma A, et al,. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol, 2012; 74: 490-500.
54. Lang D, Freudenberger C, Weinz C,. In vitro metabolism of rivaroxaban-an oral, direct Factor Xa inhibitor-in liver microsomes and hepatocytes of rat, dog and man. Drug Metab Dispos, 2009; 37: 1046-1055.
55. Mueck W, Kubitza D, Becka M,. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol, 2013; 76: 455-466.
56. Kubitza D, Becka M, Roth A, Mueck W,. Absence of clinically relevant interactions between rivaroxaban-an oral, direct Factor Xa inhibitor-and digoxin or atorvastatin in healthy subjects. J Int Med Res, 2012; 40: 1688-1707.
57. Kubitza D, Becka M, Mueck W, Zuehlsdorf M,. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Br J Clin Pharmacol, 2007; 63: 469-476.
58. Kubitza D, Becka M, Mueck W, Schwers S,. Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study. Pharmaceuticals (Basel), 2012; 5: 279-296.
59. Kubitza D, Becka M, Mueck W, Zuehlsdorf M,. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct Factor Xa inhibitor-are not affected by aspirin. J Clin Pharmacol, 2006; 46: 981-990.
60. Kubitza D, Becka M, Schwers S, Voith B,. Investigation of pharmacodynamic and pharmacokinetic interactions between rivaroxaban and enoxaparin in healthy male subjects. Clin Pharmacol Drug Dev, 2013; 2: 270-277.
61. Upreti VV, Song Y, Wang J, et al,. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct Factor Xa inhibitor. Clin Pharmacol, 2013; 5: 59-66.
62. Connolly SJ, Ezekowitz MD, Yusuf S, et al,. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361: 1139-1151.
63. Patel MR, Mahaffey KW, Garg J, et al,. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 883-891.
64. Granger CB, Alexander JH, McMurray JJ, et al,. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365: 981-992.
65. Connolly SJ, Eikelboom J, Joyner C, et al,. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011; 364: 806-817.
66. Connolly SJ, Wallentin L, Ezekowitz MD, et al,. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation, 2013; 128: 237-243.
67. Hori M, Matsumoto M, Tanahashi N, et al,. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ J, 2012; 76: 2104-2111.
68. Mega JL, Braunwald E, Wiviott SD, et al,. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 366: 9-19.
69. Alexander JH, Lopes RD, James S, et al,. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med, 2011; 365: 699-708.
70. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM,. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol, 2010; 27: 999-1015.
71. Sié P, Samama CM, Godier A, et al,. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or Factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis, 2011; 104: 669-676.
72. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012; 366: 1287-1297.
73. Samama MM, Guinet C,. Laboratory assessment of new anticoagulants. Clin Chem Lab Med, 2011; 49: 761-772.
74. Gruber A, Carlsson S, Kotze HF, Marzec U, Sarich TC, Hanson SR,. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates. Thromb Res, 2007; 119: 121-127.
75. Godier A, Miclot A, Le Bonniec B, et al,. Evaluation of prothrombin complex concentrate and recombinant activated Factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 2012; 116: 94-102.
76. Pragst I, Zeitler SH, Doerr B, et al,. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost, 2012; 10: 1841-1848.
77. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M,. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 2011; 124: 1573-1579.
78. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G,. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost, 2012; 108: 217-224.
79. Peacock WF, Gearhart MM, Mills RM,. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol, 2012; 35: 730-737.
80. Lu G, DeGuzman FR, Hollenbach SJ, et al,. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation Factor Xa. Nat Med, 2013; 19: 446-451.
81. Schiele F, van Ryn J, Canada K, et al,. A specific antidote for dabigatran: functional and structural characterization. Blood, 2013; 121: 3554-3562.
82. Stangier J,. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet, 2008; 47: 285-295.